Clinical Trial Update: Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating nab-paclitaxel plus carboplatin and a PD-1 inhibitor as neoadjuvant therapy for early-stage triple-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING